Pamrevlumab - FibroGen

Drug Profile

Pamrevlumab - FibroGen

Alternative Names: Anti-CTGF antibody; FG-3019; Pamrevlumab

Latest Information Update: 14 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator FibroGen
  • Class Antifibrotics; Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Connective tissue growth factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer; Idiopathic pulmonary fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Duchenne muscular dystrophy; Hepatic fibrosis; Idiopathic pulmonary fibrosis; Pancreatic cancer
  • No development reported Glioblastoma; Glomerulonephritis
  • Discontinued Diabetic cardiomyopathy; Diabetic nephropathies; Diabetic neuropathies

Most Recent Events

  • 14 Nov 2017 FibroGen plans a phase III trial for Idiopathic pulmonary fibrosis
  • 08 Nov 2017 FibroGen intends to define registrational strategy for pamrevlumab for Pancreatic cancer in the first half of 2018
  • 08 Nov 2017 FibroGen completes the phase II PRAISE trial in Idiopathic pulmonary fibrosis in Australia, Bulgaria, India and New Zealand (IV) before November 2017 (NCT01890265)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top